T4 rectal cancer. Surgery and multimodal therapy [T4-Rektumkarzionom: Operative und multimodale Therapie]

被引:0
|
作者
Rau B. [1 ]
Hohenberger P. [1 ]
Gellermann J. [2 ]
Hünerbein M. [1 ]
Hildebrandt B. [3 ]
Schneider U. [1 ,4 ]
Riess H. [3 ]
Wust P. [2 ]
Schlag P.M. [1 ,5 ]
机构
[1] Robert-Rössle-Klin., Char., Camp. Buch im Helios-Klinikum Berlin, Berlin
[2] Radiol. und Strahlenklinik, Char., Campus Virchow-Klinikum, Humboldt Universität, Berlin
[3] Med. Klin. Poliklin., Virchow-Klinikum, Humboldt Universität, Berlin
[4] Pathologie, Charité, Campus Mitte, Humboldt Universität, Berlin
[5] Robert-Rössle-Klin., Char., Camp. Buch im Helios-Klinikum Berlin
来源
Der Chirurg | 2002年 / 73卷 / 2期
关键词
Downstaging; Preoperative radiochemotherapy; Rectal cancer;
D O I
10.1007/s00104-001-0373-5
中图分类号
学科分类号
摘要
Background. In locally advanced rectal cancer with infiltration of neighbouring organs (uT4), resectability and local control are difficult to achieve. Combined preoperative radiochemotherapy may result in increased resectability and reduced local recurrence rates. Patients and methods. Thirty-four patients with biopsy-proven locally advanced rectal cancer were treated by preoperative radiochemotherapy. All tumours had been staged as uT4 lesions by endorectal ultrasound or computed tomography. Radiotherapy was applied in standard blocks, 5×1.8 Gy up to 45 Gy.Chemotherapy consisted of two cycles of 5-fluorouracil (300-350 mg/m2/day) and leucovorin (50 mg).ln 20 patients,additional thermotherapy was carried out using the Sigma 60 applicator BSD 2000 once a week prior to radiotherapy.Surgery was performed 4-6 weeks after radiochemotherapy. Postoperatively,all patients received four cycles of 5-fluorouracil and leucovorin. Results. Treatment-induced toxicity occurred in 26% of the patients (WHO grade III (n = 6) and IV (n = 3)).The resectability rate was 76% (26/34 patients) (RO resectability n = 21;62%).The pathological complete response rate was 6% (n = 2) and the partial response rate was 47% (n -16). A local failure was observed in six patients after median time of 16 months (range 7-36 months). Patients with RO resection achieved a 5-year disease-free survival rate of 55% and a survival rate of 71%.The overall 5-year survival rate for all patients with advanced uT4 rectal cancer was 49%. Conclusions. Our data on preoperative combined treatment in locally advanced T4 rectal cancer revealed encouraging downstaging, local control,and survival rates.
引用
收藏
页码:147 / 153
页数:6
相关论文
共 50 条
  • [41] PERSISTENT HIGH POSITIVE CIRCUMFERENTIAL RESECTION MARGINS AFTER NEOADJUVANT TREATMENT IN CLINICALLY STAGED T4 RECTAL CANCER.
    de Nes, L. C.
    Drager, L.
    Burger, P.
    de Wilt, H.
    Tanis, P.
    [J]. DISEASES OF THE COLON & RECTUM, 2020, 63 (06) : E404 - E404
  • [42] Benefit of adjuvant chemotherapy in patients with T4, UICC II colon cancer.
    Teufel, Andreas
    Gerken, Michael
    Hartl, Janine
    Itzel, Timo
    Fichtner-Feigl, Stefan
    Stroszczynski, Christian
    Schlitt, Hans J.
    Hofstaedter, Ferdinand
    Klinkhammer-Schalke, Monika
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [43] Multicentre propensity score-matched analysis of laparoscopic versus open surgery for T4 rectal cancer
    de'Angelis, Nicola
    Landi, Filippo
    Vitali, Giulio Cesare
    Memeo, Riccardo
    Martinez-Perez, Aleix
    Solis, Alejandro
    Assalino, Michela
    Vallribera, Francesc
    Mercoli, Henry Alexis
    Marescaux, Jacques
    Mutter, Didier
    Ris, Frederic
    Espin, Eloy
    Brunetti, Francesco
    [J]. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2017, 31 (08): : 3106 - 3121
  • [44] Multicentre propensity score-matched analysis of laparoscopic versus open surgery for T4 rectal cancer
    Nicola de’Angelis
    Filippo Landi
    Giulio Cesare Vitali
    Riccardo Memeo
    Aleix Martínez-Pérez
    Alejandro Solis
    Michela Assalino
    Francesc Vallribera
    Henry Alexis Mercoli
    Jacques Marescaux
    Didier Mutter
    Frédéric Ris
    Eloy Espin
    Francesco Brunetti
    [J]. Surgical Endoscopy, 2017, 31 : 3106 - 3121
  • [45] Multicenter propensity score matched analysis of laparoscopic vs. open surgery for T4 rectal cancer
    Vitali, G.
    Deangelis, N.
    Landi, F.
    Assalino, M.
    Memeo, R.
    Marescaux, J.
    Ris, F.
    Espin, E.
    Brunetti, F.
    [J]. BRITISH JOURNAL OF SURGERY, 2017, 104 : 7 - 7
  • [46] Extended surgery for T4 lung cancer: a 30 years' experience
    Dartevelle, P. G.
    Mitilian, D.
    Fadel, E.
    [J]. GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2017, 65 (06) : 321 - 328
  • [47] Surgery for T4 non-small cell lung cancer
    Pramesh, CS
    Mistry, RC
    Pantvaidya, GH
    Raina, S
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2004, 25 (04) : 661 - 661
  • [48] Surgery for T4 non-small cell lung cancer
    Prokakis, Chr
    Apostolakis, E.
    Koletsis, E.
    Panagopoulos, N.
    Stamou-Kouki, E.
    Filos, K.
    Dougenis, D.
    [J]. LUNG CANCER, 2007, 55 : S15 - S15
  • [49] Extended surgery for T4 lung cancer: a 30 years’ experience
    P. G. Dartevelle
    D. Mitilian
    E. Fadel
    [J]. General Thoracic and Cardiovascular Surgery, 2017, 65 : 321 - 328
  • [50] Surgery for T4 Colorectal Cancer in Older Patients: Determinants of Outcomes
    Osseis, Michael
    Nehmeh, William A.
    Rassy, Nathalie
    Derienne, Joseph
    Noun, Roger
    Salloum, Chady
    Rassy, Elie
    Boussios, Stergios
    Azoulay, Daniel
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (09):